Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

EQS-News: Annual General Meeting of Eckert & Ziegler SE Approves Split-Off of Pentixapharm AG


EQS-News: Eckert Ziegler SE / Key word(s): AGM/EGM
Annual General Meeting of Eckert Ziegler SE Approves Split-Off of Pentixapharm AG

26.06.2024 / 16:27 CET/CEST
The issuer is solely responsible for the content of this announcement.


Berlin, June 26, 2024. The Annual General Meeting of Eckert Ziegler SE (ISIN DE0005659700) today resolved to split-off Pentixapharm AG from Eckert Ziegler SE and to distribute a dividend of EUR 0.05 per share for the 2023 financial year.

As in the previous year, the Annual General Meeting was held as an in-person event at Eckert Ziegler SE's headquarters in Berlin. A total of 57.6% of the company's share capital was represented.

The detailed voting results of the Annual General Meeting and the presentation by the Chairman of the Executive Board are published on the Eckert Ziegler SE website:
https://www.ezag.com/home/investors/annual_general_meeting/

About Eckert Ziegler
Eckert Ziegler SE with more than 1.000 employees is a leading specialist for isotope-related components in nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.

Your contact:
Eckert Ziegler SE, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, [email protected], www.ezag.com 



26.06.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: Eckert Ziegler SE
Robert-Rössle-Str.10
13125 Berlin
Germany
Phone: +49 30 941084-138
Fax: +49 30 941084-0
Internet: www.ezag.de
ISIN: DE0005659700
WKN: 565970
Indices: SDAX, TecDax,
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1933989

 
End of News EQS News Service

1933989  26.06.2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1933989&application_name=news&site_id=sharewise~~~202ee175-2c72-4a50-a0f7-89cd8fcfa533

Eckert & Ziegler Strahlen- und Medizintechnik AG Aktie

40,36 €
-2,42 %
Die Eckert & Ziegler Strahlen- und Medizintechnik AG Aktie verzeichnet heute einen spürbaren Rückgang um -2,42 %.
Die Eckert & Ziegler Strahlen- und Medizintechnik AG Aktie genießt klare Unterstützung: Mehrere Buy-Einschätzungen, keine Sell-Einschätzungen.
Die Community prognostiziert für Eckert & Ziegler Strahlen- und Medizintechnik AG ein Kursziel von 95 €, was eine Steigerung von mehr als 100% gegenüber dem aktuellen Kurs von 40.36 € bedeutet.
Like: 0
Teilen
EQS Group is a leading international provider of regulatory technology in the fields of corporate compliance and investor relations. In working with EQS Group, thousands of companies worldwide inspire trust by fulfilling complex national and international disclosure obligations, minimizing risks and communicating transparently with stakeholders.




Rechtlicher Hinweis

Kommentare